sh-Oligopeptide-1 (Human EGF)
Also known as: rh-EGF, Epidermal growth factor (cosmetic)
sh-Oligopeptide-1 (Human EGF), also called rh-EGF or Epidermal growth factor (cosmetic), is a research peptide in the Growth-factor mimetic class. Human epidermal growth factor is a 53-amino-acid protein that binds EGFR, a receptor tyrosine kinase, triggering dimerisation, autophosphorylation and downstream MAPK and PI3K/Akt signalling.
For research use only.
Key Facts
- CAS
- 62253-63-8
- Molecular Weight (MW)
- ≈6.2 kDa (protein growth factor)
- Half-life
- Topical; systemic PK not applicable
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- EGFR
Research summary
Recombinant or fragment EGF used in cosmetics as sh-oligopeptide-1. Topical cosmetic; injectable EGF is a different, unapproved proposition.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials1 reviewed source
- Early or uncontrolled human studiesOnly in 1 review or summary
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's sh-Oligopeptide-1 (Human EGF) profile summarises 2 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
sh-Oligopeptide-1 (Human EGF) dosage: no established human dose
sh-Oligopeptide-1 (a cosmetic recombinant EGF) has no established human dosage. It is used in topical serums. In a 12-week randomised double-blind pilot, 20 women applied an oligopeptide-1 serum or a human-derived growth factor serum twice daily. A 2023 review argues that the cosmetic ingredient has not been shown to work as functional EGF.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: sh-Oligopeptide-1 is a cosmetic ingredient considered to be the equivalent of human epidermal growth factor (EGF). Its human evidence is small studies of topical serums, and a critical review questions whether the cosmetic ingredient is biologically active. No study of the cosmetic ingredient given by injection was found, so no injectable amount, route or interval is established.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Topical (cosmetic serums) |
| Frequency | Twice daily in the published pilot |
| Duration studied | 12 weeks in the published pilot |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-11-07 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Randomised double-blind pilot — facial photoageing (Abud et al., 2026)Clinical trial · Pilot randomised trial with an active comparator | 20 women aged 50–65 with moderate to severe facial photoageing | Serum strength not stated in the indexed abstract; recombinant EGF (oligopeptide-1) serum vs a human-derived growth factor serum | Topical (face) | Twice daily, with a standard cleanser and sunscreen | 12 weeks | Investigator ratings of texture and firmness favoured the oligopeptide-1 serum at later visits; wrinkle severity changed little in either group | Abud B et al. A Randomized, Double-Blinded Pilot Study Comparing Synthetic Versus Human-Derived Topical Epidermal Growth Factor for Facial Rejuvenation and Psychosocial Perception. J Cosmet Dermatol. 2026. |
| Systematic review — sh-oligopeptide-1 in cosmetic clinical trials (Martínez-Carpio, 2023)Research-reported · Systematic search and critical review | 12 articles, 9 of them clinical trials that used sh-oligopeptide-1 as if it were recombinant human EGF | Not applicable | Topical preparations | — | — | The author concludes that the preclinical bioactivity of sh-oligopeptide-1 has not been proven, that it is not a functional EGF, and that topical recombinant human EGF is not authorised as a medicine except in clinical trials | Martínez-Carpio PA. Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud? Cutan Ocul Toxicol. 2023. |
Where sources disagree
- A percentage or ppm in a cream is a formulation strength, not a dose, and cannot be converted into an amount for injection.
- The cosmetic ingredient and medicinal recombinant EGF products are not interchangeable. Studies of a medicinal EGF product are not evidence for a cosmetic serum ingredient, and the reverse.
Sequence & molecular data
| Molecular formula | C270H401N73O83S7 |
|---|---|
| Molecular weight | ≈6.2 kDa (protein growth factor) |
| CAS number | 62253-63-8 |
| Half-life | Topical; systemic PK not applicable |
| Appearance | White lyophilized powder (recombinant protein) |
| Formulation | Topical Cream |
| PubChem CID | 177865760 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Human epidermal growth factor is a 53-amino-acid protein that binds EGFR, a receptor tyrosine kinase, triggering dimerisation, autophosphorylation and downstream MAPK and PI3K/Akt signalling. In wound and cosmetic models this drives keratinocyte migration and proliferation and fibroblast activity, the basis for its use in topical repair and anti-ageing formulations. The practical constraint is delivery: at roughly 6 kDa the intact protein is far above the size that passively crosses an intact stratum corneum, so meaningful penetration depends on formulation, carriers, or compromised barrier function. Claims about topical activity should be read against that limitation.
Origin
Recombinant EGF or cosmetic oligopeptide listing.
Targets
Studies
Research statistics
3 PubMed publications · 66.7% human clinical research · 1 registered trial
Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
sh-Oligopeptide-1 (Human EGF) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | OTC / Supplement |
| WADA (sport) | Permitted |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
sh-Oligopeptide-1 (Human EGF) side effects
sh-Oligopeptide-1 (Human EGF) has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Irritation
- Theoretical EGFR stimulation concerns
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
sh-Oligopeptide-1 (Human EGF): frequently asked questions
What is sh-Oligopeptide-1 (Human EGF)?
Recombinant or fragment EGF used in cosmetics as sh-oligopeptide-1. Topical cosmetic; injectable EGF is a different, unapproved proposition.
How does sh-Oligopeptide-1 (Human EGF) work?
Human epidermal growth factor is a 53-amino-acid protein that binds EGFR, a receptor tyrosine kinase, triggering dimerisation, autophosphorylation and downstream MAPK and PI3K/Akt signalling. In wound and cosmetic models this drives keratinocyte migration and proliferation and fibroblast activity, the basis for its use in topical repair and anti-ageing formulations.
Is sh-Oligopeptide-1 (Human EGF) FDA approved?
No. sh-Oligopeptide-1 (Human EGF) is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of sh-Oligopeptide-1 (Human EGF)?
Reported half-life for sh-Oligopeptide-1 (Human EGF) is Topical; systemic PK not applicable. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is sh-Oligopeptide-1 (Human EGF) banned in sport?
sh-Oligopeptide-1 (Human EGF) is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to sh-Oligopeptide-1 (Human EGF)?
Compounds most often compared with sh-Oligopeptide-1 (Human EGF) include Acetyl Hexapeptide-8, Acetyl Octapeptide-3, Acetyl Tetrapeptide-3 and AHK-Cu. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- A Randomized, Double-Blinded Pilot Study Comparing Synthetic Versus Human-Derived Topical Epidermal Growth Factor for Facial Rejuvenation and Psychosocial Perception — J Cosmet Dermatol, 2026External reference
- Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud? — Cutan Ocul Toxicol, 2023External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This sh-Oligopeptide-1 (Human EGF) profile is compiled from published literature (2 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track sh-Oligopeptide-1 (Human EGF) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →